140 related articles for article (PubMed ID: 24222118)
1. Human pancreatic cancer cells with acquired gemcitabine resistance exhibit significant up-regulation of peroxiredoxin-2 compared to sensitive parental cells.
Suenaga S; Kuramitsu Y; Wang Y; Baron B; Kitagawa T; Akada J; Tokuda K; Kaino S; Maehara S; Maehara Y; Sakaida I; Nakamura K
Anticancer Res; 2013 Nov; 33(11):4821-6. PubMed ID: 24222118
[TBL] [Abstract][Full Text] [Related]
2. Up-regulation of DDX39 in human pancreatic cancer cells with acquired gemcitabine resistance compared to gemcitabine-sensitive parental cells.
Kuramitsu Y; Suenaga S; Wang Y; Tokuda K; Kitagawa T; Tanaka T; Akada J; Maehara S; Maehara Y; Nakamura K
Anticancer Res; 2013 Aug; 33(8):3133-6. PubMed ID: 23898070
[TBL] [Abstract][Full Text] [Related]
3. Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine.
Mori-Iwamoto S; Kuramitsu Y; Ryozawa S; Mikuria K; Fujimoto M; Maehara S; Maehara Y; Okita K; Nakamura K; Sakaida I
Int J Oncol; 2007 Dec; 31(6):1345-50. PubMed ID: 17982661
[TBL] [Abstract][Full Text] [Related]
4. Heat-shock protein 27 is phosphorylated in gemcitabine-resistant pancreatic cancer cells.
Taba K; Kuramitsu Y; Ryozawa S; Yoshida K; Tanaka T; Maehara S; Maehara Y; Sakaida I; Nakamura K
Anticancer Res; 2010 Jul; 30(7):2539-43. PubMed ID: 20682980
[TBL] [Abstract][Full Text] [Related]
5. Active hexose-correlated compound down-regulates HSP27 of pancreatic cancer cells, and helps the cytotoxic effect of gemcitabine.
Suenaga S; Kuramitsu Y; Kaino S; Maehara S; Maehara Y; Sakaida I; Nakamura K
Anticancer Res; 2014 Jan; 34(1):141-6. PubMed ID: 24403454
[TBL] [Abstract][Full Text] [Related]
6. Active Hexose-correlated Compound Down-regulates Heat Shock Factor 1, a Transcription Factor for HSP27, in Gemcitabine-resistant Human Pancreatic Cancer Cells.
Tokunaga M; Baron B; Kitagawa T; Tokuda K; Kuramitsu Y
Anticancer Res; 2015 Nov; 35(11):6063-7. PubMed ID: 26504030
[TBL] [Abstract][Full Text] [Related]
7. Identification of up- and down-regulated proteins in gemcitabine-resistant pancreatic cancer cells using two-dimensional gel electrophoresis and mass spectrometry.
Kuramitsu Y; Taba K; Ryozawa S; Yoshida K; Zhang X; Tanaka T; Maehara S; Maehara Y; Sakaida I; Nakamura K
Anticancer Res; 2010 Sep; 30(9):3367-72. PubMed ID: 20944110
[TBL] [Abstract][Full Text] [Related]
8. High-mobility Group Box 1 and Mitogen-activated Protein Kinase activated Protein Kinase-2 Are Up-regulated in Gemcitabine-resistant Pancreatic Cancer Cells.
Kuramitsu Y; Wang Y; Kitagawa T; Tokuda K; Akada J; Tokunaga M; Nakamura K
Anticancer Res; 2015 Jul; 35(7):3861-5. PubMed ID: 26124331
[TBL] [Abstract][Full Text] [Related]
9. Selenoprotein P, as a predictor for evaluating gemcitabine resistance in human pancreatic cancer cells.
Maehara S; Tanaka S; Shimada M; Shirabe K; Saito Y; Takahashi K; Maehara Y
Int J Cancer; 2004 Nov; 112(2):184-9. PubMed ID: 15352029
[TBL] [Abstract][Full Text] [Related]
10. KNK437 downregulates heat shock protein 27 of pancreatic cancer cells and enhances the cytotoxic effect of gemcitabine.
Taba K; Kuramitsu Y; Ryozawa S; Yoshida K; Tanaka T; Mori-Iwamoto S; Maehara S; Maehara Y; Sakaida I; Nakamura K
Chemotherapy; 2011; 57(1):12-6. PubMed ID: 21124027
[TBL] [Abstract][Full Text] [Related]
11. Comparative proteomic analysis of two stress-management strategies in pancreatic cancer.
Baron B; Fujioka T; Kitagawa T; Maehara S; Maehara Y; Nakamura K; Kuramitsu Y
Cancer Genomics Proteomics; 2015; 12(2):83-7. PubMed ID: 25770192
[TBL] [Abstract][Full Text] [Related]
12. CUB Domain-containing Protein 1 (CDCP1) Is Down-regulated by Active Hexose-correlated Compound in Human Pancreatic Cancer Cells.
Kuhara K; Tokuda K; Kitagawa T; Baron B; Tokunaga M; Harada K; Terasaki M; Uehara O; Ohta T; Takai R; Hamada JI; Kobayashi M; Shimo T; Nagayasu H; Kuramitsu Y
Anticancer Res; 2018 Nov; 38(11):6107-6111. PubMed ID: 30396925
[TBL] [Abstract][Full Text] [Related]
13. Enzyme-treated Asparagus Extract Down-regulates Heat Shock Protein 27 of Pancreatic Cancer Cells.
Shimada T; Nanimoto Y; Baron B; Kitagawa T; Tokuda K; Kuramitsu Y
In Vivo; 2018; 32(4):759-763. PubMed ID: 29936456
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of gemcitabine sensitivity in pancreatic cancer by co-regulation of dCK and p8 expression.
Tang K; Zhang Z; Bai Z; Ma X; Guo W; Wang Y
Oncol Rep; 2011 Apr; 25(4):963-70. PubMed ID: 21225236
[TBL] [Abstract][Full Text] [Related]
15. Insights into gemcitabine resistance and the potential for therapeutic monitoring.
Gebregiworgis T; Bhinderwala F; Purohit V; Chaika NV; Singh PK; Powers R
Metabolomics; 2018 Nov; 14(12):156. PubMed ID: 30830412
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.
Nakano Y; Tanno S; Koizumi K; Nishikawa T; Nakamura K; Minoguchi M; Izawa T; Mizukami Y; Okumura T; Kohgo Y
Br J Cancer; 2007 Feb; 96(3):457-63. PubMed ID: 17224927
[TBL] [Abstract][Full Text] [Related]
17. Ratio of phosphorylated HSP27 to nonphosphorylated HSP27 biphasically acts as a determinant of cellular fate in gemcitabine-resistant pancreatic cancer cells.
Kang D; Choi HJ; Kang S; Kim SY; Hwang YS; Je S; Han Z; Kim JH; Song JJ
Cell Signal; 2015 Apr; 27(4):807-17. PubMed ID: 25615626
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiD™ lenalidomide.
Fryer RA; Barlett B; Galustian C; Dalgleish AG
Anticancer Res; 2011 Nov; 31(11):3747-56. PubMed ID: 22110196
[TBL] [Abstract][Full Text] [Related]
19. [The mechanism of resistance to 2', 2'-difluorodeoxycytidine (gemcitabine) in a pancreatic cancer cell line].
Yao J; Feng FY; Lin C; Zhang XY; Fu M; Liang X; Yang Y
Zhonghua Zhong Liu Za Zhi; 2005 Dec; 27(12):721-6. PubMed ID: 16483481
[TBL] [Abstract][Full Text] [Related]
20. Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer.
Kawaguchi K; Miyake K; Han Q; Li S; Tan Y; Igarashi K; Kiyuna T; Miyake M; Higuchi T; Oshiro H; Zhang Z; Razmjooei S; Wangsiricharoen S; Bouvet M; Singh SR; Unno M; Hoffman RM
Cancer Lett; 2018 Sep; 432():251-259. PubMed ID: 29928962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
